Genocea stops pneumonia vaccine development after study fails
Oct 19 (Reuters) - Drug developer Genocea Biosciences Inc said it was suspending the development of a vaccine for pneumonia-causing bacteria after it failed to significantly reduce infection in a mid-stage study.
During the trial, which included 98 adults, the vaccine showed consistent reductions in bacterial infection when compared with a placebo, but was not able to achieve statistical significance.
(Reporting by Amrutha Penumudi in Bengaluru; Editing by Don Sebastian)
Terms and Privacy Policy